Background-Ample evidence demonstrates cardiovascular protection by incretin-based therapy using dipeptidyl peptidase 4 inhibitor (DPP4i) and glucagon-like peptide-1 (GLP-1) under either diabetic or nondiabetic condition. Their action on myocardium is mediated by the cyclic AMP (cAMP) signal; however, the pathway remains uncertain. This study was conducted to address the effect of DPP4i/GLP-1/cAMP axis on cardiac dysfunction and remodeling induced by pressure overload (thoracic aortic constriction [TAC]) independently of diabetes mellitus.
D ipeptidyl peptidase 4 inhibitor (DPP4i) is among the most popular antidiabetic remedies worldwide, and its substrate glucagon-like peptide-1 (GLP-1), an incretin hormone, primarily mediates the drug class effects of DPP4i. 1 To date, ample preclinical evidence has demonstrated the pleiotropic effects of DPP4i and GLP-1 analogs on the cardiovascular protection, 2,3 including heart failure (HF). [4] [5] [6] [7] Recent clinical evidence exploring the effect of DPP4i on cardiovascular safety in patients with type 2 diabetes mellitus reported that saxagliptin increased the incidence of hospitalization for HF via unknown mechanisms. 8, 9 In contrast, the other trials for alogliptin (ALO) 10 and sitagliptin 11 demonstrated that DPP4i did not worsen HF in type 2 diabetes mellitus. [10] [11] [12] However, the underlying mechanisms remain uncertain. 9
See Clinical Perspective
This study was conducted to address the essential effect of the DPP4i on myocardium in terms of cardiac function and remodeling using nondiabetic mice with pressure overload (thoracic aortic constriction [TAC] ). We unexpectedly found the pathological decline in casual GLP-1 level with concomitant reduction of its second messenger cyclic AMP (cAMP) concentration in myocardium of TAC, which was prevented by ALO. In the context of exploring the molecular mechanism(s) underlying the GLP-1/cAMP pathway, we found that the GLP-1-induced cAMP elevation diversely signals not only protein kinase A (PKA) but also exchange protein directly activated by cAMP 1 (EPAC1). Furthermore, we found that Distinct Roles of Cyclic AMP in Heart Failure EPAC1 was exclusively essential for cardiac survival via the small G protein Ras-related protein 1 (Rap1) activation. The present article, thus, dissected the neurohormonal significance of casual GLP-1 in response to cardiac stress independently of diabetes mellitus and the diverse roles of cAMP signaling in cardiac apoptosis.
Methods

Experimental Design
All the animal experimental procedures were approved by the Committee on the Use of Live Animals for Teaching and Research of Nagoya University and carried out in accordance with the Guideline for the Care and Use of Laboratory Animals published by the American Heart Association (1985) and the Guide for Care and Use of Laboratory Animals (1996) . The experimental protocol is illustrated in Figure I in the Data Supplement. Male C57BL6 mice were allocated into 5 groups; pressure overload induced by TAC operation with and without ALO (10 mg/kg per day for 4 weeks; TAC-ALO and TAC-CON), sham-operated counterparts (sham-ALO and sham-CON), and with exendin fragment 9-39 (inactive form of GLP-1, Ex9-39; 24 nmol/kg per day, subcutaneously administrated by osmotic pump for 4 weeks, Sigma-Aldrich, St. Louis, MO).
Echocardiography
Cardiac function of each mouse was measured using echocardiography (ACUSON Sequoia 512 system with a 15-MHz high-frequency transducer [Microson 15L8], Siemens, Pittsburgh, PA) at the time points of 4 weeks after the TAC operation under anesthesia using a combination of ketamine (75 mg/kg) and xylazine (10 mg/kg).
Analysis of Cardiac Remodeling
Cardiac capillary density and cardiomyocyte surface area were assessed by immunohistochemistry using anti-CD31 antibody (BD Biosciences, San Jose, CA) and antidystrophin antibody (Novus Biologicals, Littleton, CO). Cardiac fibrosis was assessed by using Picrosirius red staining. Each positive lesion was digitized and summarized using Image J software.
Analysis of Cardiac Apoptosis
The terminal deoxynucleotidyl transferase dUTP nick-end labeling (TUNEL) assay was performed using the DeadEnd Fluorometric TUNEL System (Promega, Fitchburg, WI), according to the manufacturer's instructions. The number of TUNEL-positive cells was expressed as the percentage of total cell number.
Cardiac cAMP Measurement and Immunoblotting
Each heart tissue was subjected to the frost shattering by using Cryopress (Microtech Nichion K.K., Chiba, Japan) to avoid any loss or degeneration during the sample processing. The cAMP concentration of each heart lysate was measured using commercially available kit (cAMP-Glo; Promega). For immunoblot analysis, tissue lysates (30 μg per lane) were incubated with Laemmli sample buffer. A list of antibodies used in this study is displayed in Table I in the Data Supplement.
RNA Silencing in Cultured Cardiomyocytes
Primary cultures of neonatal rat cardiomyocytes or H9C12 cells were plated onto an 8-well chamber slide coverslip precoated with collagen type 1 (BD Biosciences) at a density of 1×10 5 cells per well. After 24 hours of serum starvation, cardiomyocytes were treated for 24 hours with the following reagents: exendin-4 (Ex4, 30 nmol/L; Sigma-Aldrich), 8-bromoadenosine 3′,5′-cyclic monophosphate (8-Br-cAMP, 60 μmol/L; Sigma-Aldrich), Rp-adenosine 3′,5′-cyclic monophosphorothioate triethylammonium salt (a PKA inhibitor, 100 μmol/L; Sigma-Aldrich), 8-p-methoxyphenylthon-2′-O-methyl-cAMP (an EPAC inhibitor, 50 μmol/L; BioLog Life Science Institute, Bremen, Germany). Efficacy-validated siRNAs (Sigma-Aldrich) for silencing PKA (siPKA), silencing EPAC1, and a silencing negative control were introduced into cells using lipofectamine RNAiMAX (Life Technologies), according to the manufacturer's instructions.
Analysis for Rap1 Activity
Rap1 activity as a surrogate for EPAC1 activation was assessed by 2 different types of pull-down system that detects specifically active Rap1; the recombinant glutathione S-transferase-fusion protein of the Rap1-binding domain from RalGDS 13 along with glutathione agarose resin (Thermofisher Scientific) and immunoprecipitation using antiactive Rap1 antibody combined with protein G agarose (Abcam).
Analysis for PKA Activity
PKA activity was monitored to assess the effect of PKA siRNA by the use of nonradioisotope assay according to the manufacturer's protocol (PepTag Non-Radioactive cAMP-Dependent Protein KinaseAssay; Promega).
Statistical Analysis
Statistical analysis was performed using JMP Pro (version 11; SAS Institute Inc, Cary, NC). Values are expressed as the mean±SEM. Data were obtained from 14-wk-old male mice that underwent TAC or sham operation with or without ALO (10 mg/kg per day for 4 weeks). The values are the mean±SEM. %GA indicates the percent of serum-glycated albumin in total albumin (a circulating surrogate for glycemic status because %GA value increases in proportion to plasma glucose level); ALO, alogliptin; BW, body weight; HW, heart weight; HW/BW, relative ratio of HW to BW; GLU, blood glucose; and TAC, thoracic aortic constriction. *P<0.05; statistically significant interaction between the effects of TAC and ALO on each parameter by 2-way ANOVA. Group comparisons were performed by 1-way ANOVA (for parametric variables), Kruskal-Wallis ANOVA, and Mann-Whitney U test (for nonparametric) as appropriate. A 2-way ANOVA was conducted that examined the effect of TAC and ALO on baseline characteristics and cardiac function. Post hoc comparisons of considered pairs were performed using the Tukey-Kramer test for differences between means. Sample sizes and individual statistical results are provided in figure and table legends. Values of P<0.05 were considered to be statistically significant.
Results
ALO Ameliorates TAC-Induced Cardiac Dysfunction and Remodeling
We first examined the effects of ALO and TAC on the baseline characteristics (Table 1 ) and cardiac function by echocardiography (Table 2) in mice. TAC increased the heart weight/body weight ratio (Table 1 ) and promoted contractile dysfunction and myocardial hypertrophy ( Table 2) , which were restored by ALO. We next examined the molecular changes related to myocardial remodeling (Akt, mammalian target of rapamy- Figure 1J ), a thick filament protein that controls myofilament Ca 2+ sensitivity via PKA 14 signaling, and this effect was prevented by ALO. The level of phosphorylated phospholamban, which is regulated by PKA, 15 was decreased in TAC, and this effect was reversed by ALO ( Figure 1H ). In contrast, AMPK, ERK, MYH 6, troponin T-C, troponin I, and SERCA2a were upregulated in TAC but insensitive to ALO ( Figure II 
ALO Restored TAC-Induced Decreases in Circulating GLP-1 and Myocardial cAMP
The cardioprotective action of DPP4i is primarily mediated by GLP-1. 7, 16, 17 On the other hand, it remains unclear whether endogeneously secreted GLP-1 levels may be altered in response to cardiac stress likewise brain natriuretic peptide. 18 We, thus, measured the plasma GLP-1 levels in each mice (Figure 2) . Notably, TAC reduced the casual GLP-1 levels in mice (in pmol/L; 0.86±0.10 for TAC-CON versus 2.13±0.54 for Figure 2A ), and this effect was reversed by ALO. TAC/CON exhibited higher blood glucose levels (Table 1) , which is consistent with the reduced GLP-1 level, a glucose-lowering hormone. 1 No difference in body weight was observed between sham and TAC ( Table 1 ). Because GLP-1 is known as an insulinotropic hormone under diabetic conditions 1 and insulin exacerbates pressure overload HF, 19 we measured circulating insulin levels, and no significant difference was confirmed (0.71±0.12 ng/mL for TAC-CON versus 0.85±0.07 ng/mL for sham-CON, unpublished data). GLP-1 increases intracellular cAMP levels in various cell types, 1 including cardiomyocytes, which contributes to its protective effects against HF. 3, 17, 20 We, thus, measured changes in cAMP concentrations in each mouse heart ( Figure 2B ). We found a trend similar to that observed with circulating GLP-1 levels; specifically, the myocardial cAMP concentrations were reduced in TAC-CON, and this decline was prevented by ALO.
ALO Ameliorates TAC-Induced Cardiac Remodeling
We further confirmed the effect of ALO on myocardial remodeling in TAC (Figure 3 ). TAC-CON exhibited increases in cardiomyocyte surface area ( Figure 3A and 3B) and a concomitant decrease in capillary density ( Figure 3A and 3C) . ALO prevented the changes in cardiomyocyte surface area and capillary density that were partially but significantly reversed by Ex9-39, an inactive analog of GLP-1 ( Figure 3A -3C). Picrosirius red staining revealed that TAC-induced cardiac interstitial fibrosis was attenuated by ALO, which was also reversed by Ex9-39 ( Figure 3D and 3E).
ALO Reverses TAC-Induced Myocardial Apoptosis in a GLP-1-Dependent Fashion
cAMP is a unique second messenger that has diverse antiapoptotic and proapoptotic effects that are cell-type dependent. 21 In cardiomyocytes, several reports have demonstrated that an increase in cAMP augments cell apoptosis, but there are contrary studies reporting its antiapoptotic effects. 14, 21, 22 We, thus, investigated the effect of ALO/GLP-1-mediated changes in myocardial cAMP on apoptosis (Figure 4) . TAC increased the TUNEL-positive cell counts in heart ( Figure 4A and 4B), which was partially attenuated by ALO in a manner dependent on Ex9-39. In noncardiac cells, cAMP-mediated apoptosis is largely blocked by B-cell lymphoma-2 (Bcl-2). 23 Therefore, we measured changes of the Bcl-2 in each mouse heart ( Figure 4C and 4D ). We found that TAC decreased Bcl-2 levels in the heart with concomitant increase in cleaved caspase-3 levels, and these effects were completely reversed by Ex9-39 (light gray bars).
We next observed the changes in cAMP effectors in each myocardium ( Figure 4E and 4F) .
ALO augmented the phosphorylation level of cAMP response element-binding protein, 24 a surrogate for PKA activation, in TAC/CON hearts (dark gray bar, Figure 4E ), which was completely reversed by Ex9-39 (light gray bar). EPAC1 is known as another effector of cAMP, and its activation contributes to cardiomyocyte remodeling, 25, 26 contractility, 27 and apoptosis 21 in a PKA-independent fashion. 21 Myocardial EPAC1 expression was significantly augmented by TAC ( Figure 4F ), and this effect was further enhanced by ALO. In contrast, EPAC2 levels remained unchanged by TAC and by ALO ( Figure III 
GLP-1 Exerts Antiapoptotic Action in Cardiomyocytes by PKA-Independent Pathway
To address the direct action of the GLP-1/cAMP activation on cardiomyocytes, we next examined the role of PKA in apoptosis by using cultured cardiomyocytes ( Figure 5 ). In vitro TUNEL assay revealed that the topical application of the cleavage-resistant GLP-1 analog Ex4 attenuated cardiomyocyte apoptosis induced by serum depletion, which was unexpectedly insensitive to the PKA inhibitor Rp-adenosine 3′,5′-cyclic monophosphorothioate triethylammonium salt (100 μmol/L; Figure 5A ). We further confirmed the role of PKA in cardiomyocyte apoptosis in a more specific fashion using PKA-silencing RNA (siPKA; Figure 5B ). The siPKA had no effect on the Ex4-mediated cardiomyocyte survival. EPAC1 is known as another effector of cAMP, and several reports have demonstrated that EPAC1 activation contributes to cardiomyocyte remodeling, 22, 23 contractility, 24 and apoptosis 25 in a PKA-independent fashion. 25 Accordingly, we assumed that the GLP-1/cAMP axis may activate the another PKA effector EPAC1 pathway, thereby exerting its antiapoptotic action in a PKA-independent fashion in cardiomyocytes.
To test this hypothesis, we evaluated the effect of silencing EPAC1 on cardiomyocyte apoptosis ( Figure 5C ). In contrast to siPKA ( Figure 5B ), silencing EPAC1 dramatically reversed the Ex4-mediated cardiomyocyte protection in vitro. We further measured Bcl-2 expression in cultured cardiomyocytes treated with the same assay condition to explore the relationship between Bcl-2 levels and the cAMP effectors PKA (Figure 5D and 5E) and EPAC1 ( Figure 5F and 5G) . Interestingly, the siPKA had no effects on Ex4-mediated Bcl-2 upregulation, which was contrarily abrogated by the EPAC1 silencing.
Role of Rap1 in Antiapoptotic Effect of GLP-1/EPAC Axis and Its cAMP Dependency in Cardiomyocytes
To address the effect of cAMP/EPAC1 axis on cardiomyocyte apoptosis, we tested the effect of Ex4 and a cell-permeable cAMP analog (8-bromo-cAMP) on small G protein Rap1 activity in cardiomyocytes because EPAC1 specifically activates Rap1 as its guanine nucleotide exchange factor in a cAMP-dependent fashion 28 (Figure 6 ). We first compared the effect of 8-bromo-cAMP at serial concentration (in µmol/L; 0, 60, 6, and 0.06) on Rap1 activity ( Figure 6A ) and cardiomyocyte apoptosis ( Figure 6B ). 8-bromo-cAMP dose dependently activated Rap1, and the maximum response of Rap1 activation was obtained at 60 µmol/L ( Figure 6A ). We further compared Because the previous article reported that cAMP increase at nmol/L level induced by short-term exposure (<30 minutes) of phosphodiesterase inhibitors activates PKA, 29 we hypothesized whether there may be time-dependent difference in the effect of cAMP on PKA activation. We, thus, tested the short-term (20 minutes) treatment with 8-bromo-cAMP on PKA activity and found that 8-bromo-cAMP dose dependently enhanced cAMP response element-binding protein phosphorylation, suggesting that the cAMP modulates its effectors (PKA and Rap1/EPAC1) not only in a dose-dependent fashion but also in a time-dependent fashion ( Figure IV in the Data Supplement). We also found that Ex4 augmented the Rap1 activity ( Figure 6C and 6D) . Furthermore, to elucidate whether any crosslink between PKA and EPAC/Rap1 pathway, we address the effect of PKA abrogation on Rap1 activity ( Figure 6E ). The siPKA had no effect on Rap1 activity under successful abrogation of PKA expression ( Figure 6E ) and activity (Figure 6F) . Vice versa, Ex4 and 60 µmol/L 8-bromo-cAMP, of which condition promotes EPAC1 activation, did not activate PKA activity ( Figure 6F ).
Discussion
The present study demonstrated 2 essential evidences as follows: (1) the nondiabetic cardiac stress promotes pathological decline in circulating GLP-1 that causes cardiac dysfunction and remodeling independently of diabetes mellitus. (2) DPP4i/GLP-1 axis ameliorates cardiomyocyte apoptosis via EPAC1/Rap1 activation in a PKA-independent manner. One could assume that one of the reasons for this DPP4i/ GLP-1-mediated protective action may result from their effect on blood glucose level. Indeed, we found that TAC/CON exhibited significant increase in casual blood glucose level (214±15 mg/dL), which was significantly reduced by ALO (158±20 mg/dL; Table 1 ). However, there were few studies that elucidate the effect of blood glucose on myocardium in nondiabetic model, and most evidences on the pathological effects of blood glucose on myocardium were observed in diabetic models that exhibit significantly higher level of blood glucose (for instance, >400 mg/dL). 30, 31 Even in the case of these diabetic models, the effect of high glucose on myocardium becomes obvious by Figure 5 . Glucagon-like peptide-1 activation ameliorates in vitro cardiomyocyte apoptosis in a protein kinase A (PKA)-independent but exchange protein directly activated by cAMP 1 (EPAC1)-dependent fashion. A, Cardiomyocytes were exposed to serum depletion for 24 hours and subjected to treatment with exendin-4 (Ex4; 30 nmol/L) with or without the PKA inhibitor Rp-cAMP (100 μmol/L 5, [30] [31] [32] suggesting our experimental setting of 1-month exposure to pressure overload, although it leads to the mild elevation of blood glucose, presumably rules out the possible link between the effect of DPP4i/GLP-1 axis on blood glucose and those on myocardium. GLP-1 has been shown to protect cardiomyocytes from apoptosis occurred in ischemia/reperfusion models. 33, 34 We found that the decline in the casual GLP-1 level contributes to the increased cardiac apoptosis in TAC/CON by demonstrating not only the effects of DPP4i but also those GLP-1 antagonist in vivo (Figures 3 and 4) . One of the possible explanations for the pathological decline in the GLP-1 level can be found in the previous evidences demonstrating that circulating DPP4 activity is augmented in nondiabetic HF 4, 5, 35 because the DPP4 protease specifically truncates GLP-1. Akiyama et al 36 reported that the casual GLP-1 levels were reduced in patients with coronary artery disease, consistently suggesting the neurohormonal significance of the circulating GLP-1 in cardiovascular protection.
In the context of the ALO/GLP-1-mediated cardioprotective effects, we found the diverse traffic of the cAMP pathway in cardiac apoptosis ( Figures 5 and 6) . cAMP signaling is a versatile regulator of the cardiac pathophysiology that modulates apoptosis, 22 hypertrophy, 25 and contractile dysfunction. 37 To date, ample evidence indicates that cAMP signaling uses distinct effectors, namely PKA and EPAC1 14, 38 that impinge on the apoptosis regulatory molecules 14 and Ca 2+ -handling molecules. 39 Dodge-Kafka et al 29 consistently demonstrated the diversity of cAMP effectors using the models for cardiac hypertrophy. They reasoned the cause of cAMP diversity to PKA-anchoring protein that forms a complex with PKA, EPAC1, and phosphodiesterase 4D3, of which activity is regulated by the PKA-anchoring protein-associated ERK5. Considering the differences in terms of models (hypertrophy versus apoptosis) and PKA dependency on EPAC1 activation, we examined whether the EPAC1/Rap1 activation may be PKA dependent in cardiac apoptosis ( Figure 6) . Surprisingly, we found that EPAC1/Rap1 activation is PKA independent ( Figure 6E) . The possible reasons about the gap observed in the PKA dependency of EPAC1/Rap1 pathway between the study by Dodge-Kafka et al 29 and this study may account for the distinct mechanism that exists in cAMP-dependent regulation of hypertrophy and apoptosis or the different experimental condition, such as differences in process to increase intracellular cAMP (indirectly via receptor activation 21, 40 or phosphodiesterase inhibition 29 and directly by cAMP analog 21 ) and exposure time 29 ( Figure 4A ). We further examined the possible role of ERK5 in the cAMP-dependent rescue of cardiac muscle cell from apoptosis ( Figure IV in the Data Supplement). However, inhibition of ERK5 by its specific inhibitor BIX21088 had no effect on TUNEL-positive cell counts. Unexpectedly, the BIX compound reduced DAPI-positive total adhesive cell counts, suggesting that the ERK5 activity might affect cell adhesion of cardiomyocytes. Further study is awaited. The small GTPase Rap1 is evolutionarily conserved and regulates cellular proliferation, differentiation, and apoptosis, 41, 42 and Rap1 is specifically associated with cAMP and EPAC1, the Rap1 guanine nucleotide exchange factor. 43 Interestingly, Rap1 modulates cell survival by interacting with Bcl-2 in renal tubular cells. 44 Consistently, we found that cardiac Bcl-2 level is modulated in a GLP-1/EPAC1-dependent fashion ( Figure 5D-5G) . We demonstrated the concentration-dependent action of cAMP on cardiac Rap1 activity ( Figure 6A ) with concomitant changes in cardiomyocyte survival ( Figure 6B ) and PKA activity ( Figure 6F ), which was presumably regulated in time-dependent fashion ( Figure IV in the Data Supplement). Collectively, these dose and time dependency of cAMP may also account for its diversity in pathophysiological function (Figure 7) .
In cardiomyocytes, phosphodiesterase 3, together with phosphodiesterase 4, accounts for ≈90% of the basal cAMP-hydrolyzing activity. In cardiomyocyte hypertrophy, Dodge-Kafka et al 29 demonstrated the essential role of phosphodiesterase 4D3. In case of apoptosis, Ding et al [45] [46] [47] demonstrated the primary roles of phosphodiesterase 3 in cardiac muscle cell survival. Another study demonstrated that distinct phosphodiesterase subtypes alternatively modulate the cell survival pathway. 40, 46 However, we did not elucidate the link between Rap1/EPAC1 axis and phosphodiesterase subtypes.
In conclusion, this study sheds light not only on the pleiotropic action of DPP4i/GLP1 axis but also on the role of another cAMP effector Rap1/EPAC1 axis in the restoration of cardiac apoptosis, revisiting the pathophysiological significance of cAMP signaling in both healthy and diseased myocardium. Figure 7 . Schematic summary. Pressure overload promotes pathological decline in circulating glucagon-like peptide-1 (GLP-1) concentration, which was prevented by alogliptin (ALO), presumably by inhibition of dipeptidyl peptidase 4 (DPP4). GLP-1 augments cardiac cAMP signaling, both exchange protein directly activated by cAMP 1 (EPAC1) and protein kinase A (PKA); however, these effectors regulate distinct pathway. EPAC1/Rap1 axis exclusively triggers antiapoptotic effect via upregulation of B-cell lymphoma-2 (Bcl-2). PKA presumably plays a primary role in regulation of cardiac contractility. CREB indicates cAMP response element-binding protein.
